ClinicalTrials.Veeva

Menu

Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder

University of New Mexico (UNM) logo

University of New Mexico (UNM)

Status

Completed

Conditions

Opiate Antagonist Overdose
Opioid-Related Disorders

Treatments

Behavioral: Naloxone Auto-Injector

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional opioid overdose risk utilizing an evidence-based screening questionnaire.

Enrollment

402 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • All patients treated with methadone, naltrexone or buprenorphine as medication assisted treatment at the UNM Addiction and Substance Abuse Program (UNM ASAP) aged 18 or older

Exclusion criteria

  • Subjects who are allergic to naloxone and its inactive ingredients. Inactive ingredients include buffering agents.
  • Subjects younger than 18.
  • Subjects not being treated at UNM ASAP.

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

402 participants in 1 patient group

Patients with opioid substance abuse disorders
Other group
Description:
All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
Treatment:
Behavioral: Naloxone Auto-Injector

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems